The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer

David Spigel, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.

September 2, 2015

Aspirations for the Launch of Ixazomib

Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.

April 14, 2015

Unclear Diagnoses in Patients with Metastatic Disease

Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies.